The Data
/
Stocks
/ MIRM
Equity · Healthcare
MIRM
NASDAQ
Mirum Pharmaceuticals, Inc.
$118.69
+1.09% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
1D
1M
3M
1Y
5Y
All
Price · Chart
Our own end-of-day closes
10 sessions
The line runs $122 on 6 July through $118.69 on 17 July, on a scale from $115 to $130. Days the market did not trade hold the previous close, flat.
Interactive MIRM price chart by TradingView (requires JavaScript).
The chart above plots the price of MIRM over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 10 sessions over that window: $122 on 6 July 2026 through $118.69 on 17 July 2026.
Market cap
$7.7B
52-week range
$51 – $128
Avg volume
193.8K
Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Jul 17, 2026
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines for rare diseases. Its approved products include LIVMARLI (maralixibat) for cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM (cholic acid) for bile acid synthesis disorders and peroxisomal disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis. The company markets these medicines primarily in the United States, Canada, and certain European countries, and has licensing and distribution agreements for additional territories.
Company
Founded
2018
Headquarters
Foster City
Exchange
NasdaqGM
Sector
Healthcare
Class
Equity
Insiders Form 4
Filings 4 sets
MIRM insider trades
SEC Form 4 · last 90 days · newest reported trade 14 Sep 2026
Open-market buys
0
Open-market sells
9
Net sold
$13.83M
Non-trade filings
5
Date
Insider
Type
Shares
Value
14 Sep 2026
BJERKHOLT ERIC
CHIEF FINANCIAL OFFICER
Sell
9,943
$978K
02 Sep 2026
Howe Jolanda
SVP, GLOBAL CONTROLLER
Sell
658
$66K
01 Sep 2026
Peetz Christopher
CHIEF EXECUTIVE OFFICER
Sell
30,000
$2.96M
18 Aug 2026
Howe Jolanda
SVP, GLOBAL CONTROLLER
Sell
40,000
$4.00M
11 Aug 2026
BJERKHOLT ERIC
CHIEF FINANCIAL OFFICER
Sell
6,001
$600K
10 Aug 2026
Peetz Christopher
CHIEF EXECUTIVE OFFICER
Sell
20,000
$1.98M
03 Aug 2026
Howe Jolanda
SVP, GLOBAL CONTROLLER
Sell
1,840
$194K
06 Jul 2026
BJERKHOLT ERIC
CHIEF FINANCIAL OFFICER
Sell
5,000
$611K
06 Jul 2026
Peetz Christopher
CHIEF EXECUTIVE OFFICER
Sell
20,000
$2.45M
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Date
Insider
Type
Shares
Value
11 Sep 2026
BJERKHOLT ERIC
CHIEF FINANCIAL OFFICER
Option exercise
18,333
01 Sep 2026
Peetz Christopher
CHIEF EXECUTIVE OFFICER
Option exercise
30,000
$88K
18 Aug 2026
Howe Jolanda
SVP, GLOBAL CONTROLLER
Option exercise
40,000
$251K
10 Aug 2026
Peetz Christopher
CHIEF EXECUTIVE OFFICER
Option exercise
20,000
$59K
06 Jul 2026
Peetz Christopher
CHIEF EXECUTIVE OFFICER
Option exercise
20,000
$59K
MIRM reported financials
SEC EDGAR XBRL
MIRM reported revenue of $521.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$23.4M.
Figure
Reported
Period
Revenue
$521.3M
31 Dec 2025
fiscal year
Net income
−$23.4M
31 Dec 2025
fiscal year
Diluted EPS
−$0.47
31 Dec 2025
fiscal year
Total assets
$1.0B
30 Jun 2026
at period end
Total equity
−$10.4M
30 Jun 2026
at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
MIRM earnings
SEC EDGAR
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
$-1.06
—
31 Mar 2026
Q1 2026
$-13.43
—
31 Dec 2025
FY 2025
$-0.47
—
30 Sep 2025
Q3 2025
$0.05
—
30 Jun 2025
Q2 2025
$-0.12
—
31 Mar 2025
Q1 2025
$-0.30
—
31 Dec 2024
FY 2024
$-1.85
—
30 Sep 2024
Q3 2024
$-0.30
—
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
9 of the 45 institutional funds we track reported a MIRM position for the quarter ended 30 Jun 2026 — a combined $273.9M; the latest of those filings landed 02 Sep 2026.
Source: SEC EDGAR 13F filings
MIRM fails-to-deliver
SEC CNS data
On 10 Sep 2026, 27 shares of MIRM failed to deliver (about $3K) — the latest of 2 consecutive trading days with recorded fails.
Settlement date
Shares failed
Notional
% of shares out
10 Sep 2026
27
$3K
<0.001%
09 Sep 2026
17,137
$1.7M
0.026%
24 Aug 2026
30
$3K
<0.001%
Source: SEC fails-to-deliver (CNS) data